The mounting popularity of GLP-1 therapies is changing how people—and the healthcare system—address type 2 diabetes and obesity care. We'll explore the opportunities and risks of these therapies and examine the role of these medications in the long-term management of two of the costliest conditions organizations face.
Hear from our event speakers
Dr. Robert Gabbay
Chief Scientific and Medical Officer
American Diabetes Association
Dr. Tejaswi Kompala
Clinical Strategy Director for Cardiometabolic Health
Teladoc Health
Attendees will learn
- How treating obesity as a disease can help prevent progression to diabetes
- Strategies for balancing the cost of newer drugs, such as GLP-1 medications, against the potential benefits
- The value of lifestyle changes along with medications—and how to help people build better habits
